RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Clinical trials for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear

Sign up with your email to follow new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 2 Not yet finished but already full! 1

New drug duo targets genetic driver in Tough-to-Treat blood cancer

Disease control Terminated

This study is testing a combination of two oral drugs, mirdametinib and sirolimus, for people with advanced multiple myeloma that has returned or stopped responding to many other treatments and has specific genetic changes (KRAS or NRAS mutations). The goal is to find a safe dose…

Matched conditions: RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Apr 03, 2026 14:41 UTC

RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Get alerted when new RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear

New drug duo targets genetic driver in Tough-to-Treat blood cancer